-$0.15 Earnings Per Share Expected for Aevi Genomic Medicine Inc (GNMX) This Quarter

Share on StockTwits

Brokerages expect Aevi Genomic Medicine Inc (NASDAQ:GNMX) to post ($0.15) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Aevi Genomic Medicine’s earnings, with the lowest EPS estimate coming in at ($0.16) and the highest estimate coming in at ($0.13). Aevi Genomic Medicine posted earnings per share of ($0.13) during the same quarter last year, which would indicate a negative year-over-year growth rate of 15.4%. The business is expected to issue its next quarterly earnings results on Tuesday, March 12th.

According to Zacks, analysts expect that Aevi Genomic Medicine will report full year earnings of ($0.55) per share for the current financial year, with EPS estimates ranging from ($0.56) to ($0.53). For the next fiscal year, analysts expect that the business will post earnings of ($0.90) per share, with EPS estimates ranging from ($1.29) to ($0.51). Zacks’ EPS averages are an average based on a survey of sell-side research firms that follow Aevi Genomic Medicine.

Aevi Genomic Medicine (NASDAQ:GNMX) last posted its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.03.

An institutional investor recently bought a new position in Aevi Genomic Medicine stock. Wedbush Securities Inc. acquired a new stake in shares of Aevi Genomic Medicine Inc (NASDAQ:GNMX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 209,524 shares of the biotechnology company’s stock, valued at approximately $233,000. Wedbush Securities Inc. owned approximately 0.35% of Aevi Genomic Medicine as of its most recent SEC filing. Institutional investors and hedge funds own 19.61% of the company’s stock.

Shares of GNMX traded down $0.03 during mid-day trading on Friday, hitting $1.07. 51,900 shares of the company traded hands, compared to its average volume of 152,093. Aevi Genomic Medicine has a 1-year low of $0.83 and a 1-year high of $2.65. The company has a market cap of $71.24 million, a P/E ratio of -1.29 and a beta of 0.63.

Aevi Genomic Medicine Company Profile

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.

Further Reading: Asset Allocation

Get a free copy of the Zacks research report on Aevi Genomic Medicine (GNMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aevi Genomic Medicine (NASDAQ:GNMX)

Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply